DexCom, Inc. (NASDAQ:DXCM) Stock Position Lifted by Natixis Investment Managers International

Natixis Investment Managers International lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 35.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 550 shares of the medical device company’s stock after purchasing an additional 145 shares during the quarter. Natixis Investment Managers International’s holdings in DexCom were worth $234,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. Jacobi Capital Management LLC grew its position in DexCom by 31.8% in the second quarter. Jacobi Capital Management LLC now owns 87 shares of the medical device company’s stock worth $37,000 after acquiring an additional 21 shares in the last quarter. HBK Sorce Advisory LLC increased its position in shares of DexCom by 2.6% during the 2nd quarter. HBK Sorce Advisory LLC now owns 921 shares of the medical device company’s stock worth $393,000 after purchasing an additional 23 shares in the last quarter. Arkadios Wealth Advisors increased its position in shares of DexCom by 58.5% during the 2nd quarter. Arkadios Wealth Advisors now owns 65 shares of the medical device company’s stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Evolution Wealth Advisors LLC increased its position in shares of DexCom by 31.3% during the 2nd quarter. Evolution Wealth Advisors LLC now owns 109 shares of the medical device company’s stock worth $47,000 after purchasing an additional 26 shares in the last quarter. Finally, CAPROCK Group Inc. grew its holdings in DexCom by 0.8% during the 2nd quarter. CAPROCK Group Inc. now owns 3,559 shares of the medical device company’s stock worth $1,520,000 after acquiring an additional 27 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Mark G. Foletta sold 500 shares of the business’s stock in a transaction dated Friday, October 1st. The stock was sold at an average price of $543.09, for a total value of $271,545.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Andrew K. Balo sold 2,757 shares of the stock in a transaction on Tuesday, August 3rd. The stock was sold at an average price of $515.87, for a total value of $1,422,253.59. The disclosure for this sale can be found here. Insiders sold 43,766 shares of company stock valued at $22,883,487 over the last quarter. Company insiders own 0.52% of the company’s stock.

Shares of NASDAQ DXCM traded up $11.03 on Thursday, reaching $559.08. 2,165 shares of the company’s stock traded hands, compared to its average volume of 743,023. The business’s 50 day simple moving average is $533.80 and its two-hundred day simple moving average is $448.21. DexCom, Inc. has a 12 month low of $305.63 and a 12 month high of $579.00. The company has a market cap of $54.09 billion, a price-to-earnings ratio of 104.39, a price-to-earnings-growth ratio of 14.59 and a beta of 0.77. The company has a quick ratio of 5.25, a current ratio of 5.78 and a debt-to-equity ratio of 0.86.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 29th. The medical device company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.33. DexCom had a return on equity of 16.17% and a net margin of 24.45%. The firm had revenue of $595.10 million during the quarter, compared to analyst estimates of $548.02 million. Analysts forecast that DexCom, Inc. will post 2.46 earnings per share for the current fiscal year.

A number of research analysts have recently weighed in on DXCM shares. Citigroup increased their price target on DexCom from $530.00 to $630.00 and gave the company a “buy” rating in a research note on Friday, October 1st. Wells Fargo & Company increased their price objective on shares of DexCom from $380.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Friday, July 30th. Robert W. Baird raised their target price on shares of DexCom from $460.00 to $520.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Oppenheimer raised their price objective on shares of DexCom from $500.00 to $525.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Finally, Cowen cut their price objective on shares of DexCom from $540.00 to $525.00 and set an “outperform” rating for the company in a research report on Wednesday, July 21st. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has an average rating of “Buy” and an average target price of $515.13.

DexCom Profile

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

See Also: What is included in the gross domestic product?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.